Targeting the glutamatergic system to treat pathological gambling: Current evidence and future perspectives

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Pettorruso, Mauro ^a   De Risio, Luisa ^a   Martinotti, Giovanni ^b   Di Nicola, Marco ^a   Ruggeri, Filippo ^a   Conte, Gianluigi ^a   Di Giannantonio, Massimo ^b   Janiri, Luigi ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACAMPROSATE; ACETYLCYSTEINE; AMANTADINE; BACLOFEN; GABAPENTIN; GLUTAMIC ACID; MEMANTINE; MODAFINIL; PREGABALIN; TOPIRAMATE; AMINO ACID RECEPTOR AFFECTING AGENT; DOPAMINE; N METHYLASPARTIC ACID;

ADDICTION; CENTRAL NERVOUS SYSTEM; COGNITIVE DEFECT; GLUTAMATERGIC SYSTEM; HUMAN; NEUROTRANSMISSION; PATHOLOGICAL GAMBLING; PATHOPHYSIOLOGY; REVIEW; WITHDRAWAL SYNDROME; BEHAVIOR, ADDICTIVE; DRUG EFFECTS; GAMBLING; MALE; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; SYNAPTIC TRANSMISSION;

BEHAVIOR, ADDICTIVE; DOPAMINE; EXCITATORY AMINO ACID AGENTS; GAMBLING; GLUTAMIC ACID; HUMANS; MALE; MOLECULAR TARGETED THERAPY; N-METHYLASPARTATE; SYNAPTIC TRANSMISSION;

EID: 84903591999     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/109786     Document Type: Review

References (73)

1. Hodgins D. C., Stea J. N., Grant J. E., Gambling disorders. The Lancet 2011 378 9806 1874 1884 2-s2.0-82255175195 10.1016/S0140-6736(10)62185-X
2. Kalivas P. W., The glutamate homeostasis hypothesis of addiction. Nature Reviews Neuroscience 2009 10 8 561 572 2-s2.0-67651083577 10.1038/nrn2515
3. Krupitsky E. M., Rudenko A. A., Burakov A. M., Slavina T. Y., Grinenko A. A., Pittman B., Gueorguieva R., Petrakis I. L., Zvartau E. E., Krystal J. H., Antiglutamatergic strategies for ethanol detoxification: comparison with placebo and diazepam. Alcoholism: Clinical and Experimental Research 2007 31 4 604 611 2-s2.0-33947221100 10.1111/j.1530-0277.2007.00344.x (Pubitemid 46434897)
4. Rösner S., Leucht S., Lehert P., Soyka M., Acamprosate supports abstinence, naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes. Journal of Psychopharmacology 2008 22 1 11 23 2-s2.0-37749032186 10.1177/0269881107078308
5. Potenza M. N., The neurobiology of pathological gambling and drug addiction: an overview and new findings. Philosophical Transactions of the Royal Society B: Biological Sciences 2008 363 1507 3181 3189 2-s2.0-51449085123 10.1098/rstb.2008.0100
6. Black D. W., McNeilly D. P., Burke W. J., Shaw M. C., Allen J., An open-label trial of acamprosate in the treatment of pathological gambling. Annals of Clinical Psychiatry 2011 23 4 250 256 2-s2.0-84858314840
7. Dannon P. N., Rosenberg O., Schoenfeld N., Kotler M., Acamprosate and baclofen were not effective in the treatment of pathological gambling: preliminary blind rater comparison study. Frontiers in Psychiatry 2011 2, article 33 2-s2.0-84866156100 10.3389/fpsyt.2011.00033
8. Pettorruso M., Martinotti G., di Nicola M., Onofrj M., di Giannantonio M., Conte G., Janiri L., Amantadine in the treatment of pathological gambling: a case report. Frontiers in Psychiatry 2012 3, article 102 2-s2.0-84870921510 10.3389/fpsyt.2012.00102
9. Thomas A., Bonanni L., Gambi F., Di Iorio A., Onofrj M., Pathological gambling in parkinson disease is reduced by amantadine. Annals of Neurology 2010 68 3 400 404 2-s2.0-77956359289 10.1002/ana.22029
10. Pettorruso M., Conte G., Righino E., di Cesare A., Chiappini S., Testa R., Janiri L., 2876-Glutamatergic strategies in the treatment of pathological gambling: a pilot study. European Psychiatry 2013 28 supplement 1 1 10.1016/S0924-9338(13)77453-4
11. Grant J. E., Chamberlain S. R., Odlaug B. L., Potenza M. N., Kim S. W., Memantine shows promise in reducing gambling severity and cognitive inflexibility in pathological gambling: a pilot study. Psychopharmacology 2010 212 4 603 612 2-s2.0-78651323502 10.1007/s00213-010-1994-5
12. Pavlovic Z. M., Psychopharmacological treatment of obsessive-compulsive disorder comorbid with body dysmorphic disorder and pathological gambling disorder. Journal of Neuropsychiatry and Clinical Neurosciences 2011 23 3 E42 E43 2-s2.0-80054965990 10.1176/appi.neuropsych.23.3.E42
13. Zack M., Poulos C. X., Effects of the atypical stimulant modafinil on a brief gambling episode in pathological gamblers with high vs. low impulsivity. Journal of Psychopharmacology 2009 23 6 660 671 2-s2.0-67651149760 10.1177/0269881108091072
14. Grant J. E., Kim S. W., Odlaug B. L., N-acetyl cysteine, a glutamate-modulating agent, in the treatment of pathological gambling: a pilot study. Biological Psychiatry 2007 62 6 652 657 2-s2.0-34548150512 10.1016/j.biopsych.2006.11.021 (Pubitemid 47314380)
15. Grant J. E., Odlaug B. L., Chamberlain S. R., Potenza M. N., Schreiber L. R., Donahue C. B., Kim S. W., A randomized, placebo-controlled trial of N-acetylcysteine plus imaginal desensitization for nicotine-dependent pathological gamblers. The Journal of Clinical Psychiatry 2014 75 1 39 45 10.4088/JCP.13m08411
16. Dannon P. N., Lowengrub K., Gonopolski Y., Musin E., Kotler M., Topiramate versus fluvoxamine in the treatment of pathological gambling: a randomized, blind-rater comparison study. Clinical Neuropharmacology 2005 28 1 6 10 2-s2.0-13944282674 10.1097/01.wnf.0000152623.46474.07 (Pubitemid 40269711)
17. Berlin H. A., Braun A., Simeon D., Koran L. M., Potenza M. N., McElroy S. L., Fong T., Pallanti S., Hollander E., A double-blind, placebo-controlled trial of topiramate for pathological gambling. World Journal of Biological Psychiatry 2013 14 2 121 128 2-s2.0-84874890135 10.3109/15622975.2011.560964
18. Nicolato R., Romano-Silva M. A., Correa H., Salgado J. V., Teixeira A. L., Lithium and topiramate association in the treatment of comorbid pathological gambling and bipolar disorder. The Australian and New Zealand Journal of Psychiatry 2007 41 7 628 629 10.1080/00048670701400040
19. Dingledine R., Borges K., Bowie D., Traynelis S. F., The glutamate receptor ion channels. Pharmacological Reviews 1999 51 1 7 61 2-s2.0-0032912771 (Pubitemid 29113865)
20. Conn P. J., Pin J.-P., Pharmacology and functions of metabotropic glutamate receptors. Annual Review of Pharmacology and Toxicology 1997 37 205 237 2-s2.0-0030995878 (Pubitemid 27238875)
21. Kenny P. J., Markou A., The ups and downs of addiction: role of metabotropic glutamate receptors. Trends in Pharmacological Sciences 2004 25 5 265 272 2-s2.0-2142757234 10.1016/j.tips.2004.03.009 (Pubitemid 38553829)
22. Tzschentke T. M., Schmidt W. J., Glutamatergic mechanisms in addiction. Molecular Psychiatry 2003 8 4 373 382 2-s2.0-0038290732 10.1038/sj.mp.4001269 (Pubitemid 36609661)
23. Cornish J. L., Kalivas P. W., Cocaine sensitization and craving: differing roles for dopamine and glutamate in the nucleus accumbens. Journal of Addictive Diseases 2001 20 3 43 54 2-s2.0-0035182664 (Pubitemid 33095757)
24. Heidbreder C., Novel pharmacotherapeutic targets for the management of drug addiction. European Journal of Pharmacology 2005 526 1-3 101 112 2-s2.0-28544446057 10.1016/j.ejphar.2005.09.038 (Pubitemid 41744109)
25. Melis M., Spiga S., Diana M., The dopamine hypothesis of drug addiction: hypodopaminergic state. International Review of Neurobiology 2005 63 101 154 2-s2.0-17844390131 10.1016/S0074-7742(05)63005-X (Pubitemid 43631260)
26. Berridge K. C., Robinson T. E., What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience? Brain Research Reviews 1998 28 3 309 369 2-s2.0-0032423613 10.1016/S0165-0173(98)00019-8 (Pubitemid 29012677)
27. Potenza M. N., How central is dopamine to pathological gambling or gambling disorder? Frontiers in Behavioral Neuroscience 2013 7, article 206 10.3389/fnbeh.2013.00206
28. Pettorruso M., Martinotti G., Fasano A., Anhedonia in Parkinson's disease patients with and without pathological gambling: a case-control study. Psychiatry Research 2014 215 2 448 452 10.1016/j.psychres.2013.12.013
29. van Holst R. J., van den Brink W., Veltman D. J., Goudriaan A. E., Why gamblers fail to win: a review of cognitive and neuroimaging findings in pathological gambling. Neuroscience and Biobehavioral Reviews 2010 34 1 87 107 2-s2.0-70350225839 10.1016/j.neubiorev.2009.07.007
30. McFarland K., Lapish C. C., Kalivas P. W., Prefrontal glutamate release into the core of the nucleus accumbens mediates cocaine-induced reinstatement of drug-seeking behavior. Journal of Neuroscience 2003 23 8 3531 3537 2-s2.0-0037693859 (Pubitemid 36531996)
31. LaLumiere R. T., Kalivas P. W., Glutamate release in the nucleus accumbens core is necessary for heroin seeking. Journal of Neuroscience 2008 28 12 3170 3177 2-s2.0-41149089597 10.1523/JNEUROSCI.5129-07.2008 (Pubitemid 351442289)
32. McFarland K., Kalivas P. W., The circuitry mediating cocaine-induced reinstatement of drug-seeking behavior. Journal of Neuroscience 2001 21 21 8655 8663 2-s2.0-0035503254 (Pubitemid 33051463)
33. Nordin C., Gupta R. C., Sjödin I., Cerebrospinal fluid amino acids in pathological gamblers and healthy controls. Neuropsychobiology 2007 56 2-3 152 158 2-s2.0-40349098936 10.1159/000115782 (Pubitemid 351340029)
34. Kalivas P. W., Volkow N. D., New medications for drug addiction hiding in glutamatergic neuroplasticity. Molecular Psychiatry 2011 16 10 974 986 2-s2.0-80053131013 10.1038/mp.2011.46
35. Olive M. F., Cleva R. M., Kalivas P. W., Malcolm R. J., Glutamatergic medications for the treatment of drug and behavioral addictions. Pharmacology Biochemistry and Behavior 2012 100 4 801 810 2-s2.0-84855534956 10.1016/j.pbb.2011.04.015
36. Machado-Vieira R., Ibrahim L., Henter I. D., Zarate C. A. Jr., Novel glutamatergic agents for major depressive disorder and bipolar disorder. Pharmacology Biochemistry and Behavior 2012 100 4 678 687 2-s2.0-84855545792 10.1016/j.pbb.2011.09.010
37. di Nicola M., Bipolar disorder and gambling disorder comorbidity: current evidence and implications for pharmacological treatment. Journal of Affective Disorders. In press
38. Baker D. A., McFarland K., Lake R. W., Shen H., Tang X.-C., Toda S., Kalivas P. W., Neuroadaptations in cystine-glutamate exchange underlie cocaine relapse. Nature Neuroscience 2003 6 7 743 749 2-s2.0-0037743546 10.1038/nn1069 (Pubitemid 36792890)
39. Moran M. M., McFarland K., Melendez R. I., Kalivas P. W., Seamans J. K., Cystine/glutamate exchange regulates metabotropic glutamate receptor presynaptic inhibition of excitatory transmission and vulnerability to cocaine seeking. Journal of Neuroscience 2005 25 27 6389 6393 2-s2.0-21844443565 10.1523/JNEUROSCI.1007-05.2005 (Pubitemid 40962534)
40. Baker D. A., McFarland K., Lake R. W., Shen H., Toda S., Kalivas P. W., N-acetyl cysteine-induced blockade of cocaine-induced reinstatement. Annals of the New York Academy of Sciences 2003 1003 349 351 2-s2.0-0347722441 10.1196/annals.1300.023 (Pubitemid 38083068)
41. Kupchik Y. M., Moussawi K., Tang X.-C., Wang X., Kalivas B. C., Kolokithas R., Ogburn K. B., Kalivas P. W., The effect of N-acetylcysteine in the nucleus accumbens on neurotransmission and relapse to cocaine. Biological Psychiatry 2012 71 11 978 986 2-s2.0-84861096326 10.1016/j.biopsych.2011.10.024
42. Kalivas P. W., O'Brien C., Drug addiction as a pathology of staged neuroplasticity. Neuropsychopharmacology 2008 33 1 166 180 2-s2.0-36549053586 10.1038/sj.npp.1301564 (Pubitemid 350191316)
43. Sani G., Serra G., Kotzalidis G. D., Romano S., Tamorri S. M., Manfredi G., Caloro M., Telesforo C. L., Caltagirone S. S., Panaccione I., Simonetti A., Demontis F., Serra G., Girardi P., The role of memantine in the treatment of psychiatric disorders other than the dementias: a review of current preclinical and clinical evidence. CNS Drugs 2012 26 8 663 690 2-s2.0-84863685351 10.2165/11634390-000000000-00000
44. Van Wageningen H., Jørgensen H. A., Specht K., Hugdahl K., A 1H-MR spectroscopy study of changes in glutamate and glutamine (Glx) concentrations in frontal spectra after administration of memantine. Cerebral Cortex 2010 20 4 798 803 2-s2.0-77949363852 10.1093/cercor/bhp145
45. Leeman R. F., Potenza M. N., Similarities and differences between pathological gambling and substance use disorders: a focus on impulsivity and compulsivity. Psychopharmacology 2012 219 2 469 490 2-s2.0-84856646192 10.1007/s00213-011-2550-7
46. Fasano A., Ricciardi L., Pettorruso M., Bentivoglio A. R., Management of punding in Parkinson's disease: an open-label prospective study. Journal of Neurology 2011 258 4 656 660 2-s2.0-79953811687 10.1007/s00415-010-5817-8
47. Seppi K., Weintraub D., Coelho M., Perez-Lloret S., Fox S. H., Katzenschlager R., Hametner E.-M., Poewe W., Rascol O., Goetz C. G., Sampaio C., The movement disorder society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson's disease. Movement Disorders 2011 26 3 S42 S80 2-s2.0-80051500137 10.1002/mds.23884
48. Weintraub D., Sohr M., Potenza M. N., Siderowf A. D., Stacy M., Voon V., Whetteckey J., Wunderlich G. R., Lang A. E., Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study. Annals of Neurology 2010 68 6 963 968 2-s2.0-78650864804 10.1002/ana.22164
49. Gass J. T., Olive M. F., Glutamatergic substrates of drug addiction and alcoholism. Biochemical Pharmacology 2008 75 1 218 265 2-s2.0-36849072543 10.1016/j.bcp.2007.06.039 (Pubitemid 350235390)
50. De Witte P., Littleton J., Parot P., Koob G., Neuroprotective and abstinence-promoting effects of acamprosate: elucidating the mechanism of action. CNS Drugs 2005 19 6 517 537 2-s2.0-23044516183 10.2165/00023210- 200519060-00004 (Pubitemid 41058377)
51. Rammes G., Mahal B., Putzke J., Parsons C., Spielmanns P., Pestel E., Spanagel R., Zieglgänsberger W., Schadrack J., The anti-craving compound acamprosate acts as a weak NMDA-receptor antagonist, but modulates NMDA-receptor subunit expression similar to memantine and MK-801. Neuropharmacology 2001 40 6 749 760 2-s2.0-0035001893 10.1016/S0028-3908(01)00008-9 (Pubitemid 32436452)
52. Spanagel R., Vengeliene V., Jandeleit B., Acamprosate produces its anti-relapse effects via calcium. Neuropsychopharmacology 2014 39 4 783 791 10.1038/npp.2013.264
53. Kiefer F., Mann K., Acamprosate: how, where, and for whom does it work? Mechanism of action, treatment targets, and individualized therapy. Current Pharmaceutical Design 2010 16 19 2098 2102 2-s2.0-77955607962 10.2174/138161210791516341
54. Boothby L. A., Doering P. L., Acamprosate for the treatment of alcohol dependence. Clinical Therapeutics 2005 27 6 695 714 2-s2.0-27744484789 10.1016/j.clinthera.2005.06.015 (Pubitemid 41583518)
55. Raj Y. P., Gambling on acamprosate: a case report. Journal of Clinical Psychiatry 2010 71 9 1245 1246 2-s2.0-77957829191 10.4088/JCP.10l06059ecr
56. Chalifoux J. R., Carter A. G., GABAB receptor modulation of synaptic function. Current Opinion in Neurobiology 2011 21 2 339 344 2-s2.0-79955674106 10.1016/j.conb.2011.02.004
57. Addolorato G., Leggio L., Cardone S., Ferrulli A., Gasbarrini G., Role of the GABAB receptor system in alcoholism and stress: focus on clinical studies and treatment perspectives. Alcohol 2009 43 7 559 563 2-s2.0-70350746494 10.1016/j.alcohol.2009.09.031
58. Furieri F. A., Nakamura-Palacios E. M., Gabapentin reduces alcohol consumption and craving: a randomized, double-blind, placebo-controlled trial. Journal of Clinical Psychiatry 2007 68 11 1691 1700 2-s2.0-37049018194 (Pubitemid 350247498)
59. Martinotti G., Pregabalin in clinical psychiatry and addiction: pros and cons. Expert Opinion on Investigational Drugs 2012 21 9 1243 1245 2-s2.0-84865344642 10.1517/13543784.2012.703179
60. Cuomo I., Kotzalidis G. D., Caccia F., Danese E., Manfredi G., Girardi P., Citalopram-associated gambling: a case report. Journal of Gambling Studies 2014 30 2 467 473 10.1007/s10899-013-9360-2
61. Ballon J. S., Feifel D., A systematic review of modafinil: potential clinical uses and mechanisms of action. Journal of Clinical Psychiatry 2006 67 4 554 566 2-s2.0-33646768643 (Pubitemid 43764232)
62. Martínez-Raga J., Knecht C., Cepeda S., Modafinil: a useful medication for cocaine addiction? Review of the evidence from neuropharmacological, experimental and clinical studies. Current drug abuse reviews 2008 1 2 213 221 2-s2.0-58149270776
63. Volkow N. D., Fowler J. S., Logan J., Alexoff D., Zhu W., Telang F., Wang G.-J., Jayne M., Hooker J. M., Wong C., Hubbard B., Carter P., Warner D., King P., Shea C., Xu Y., Muench L., Apelskog-Torres K., Effects of modafinil on dopamine and dopamine transporters in the male human brain clinical implications. Journal of the American Medical Association 2009 301 11 1148 1154 2-s2.0-62649136134 10.1001/jama.2009.351
64. Ferraro L., Antonelli T., O'Connor W. T., Tanganelli S., Rambert F., Fuxe K., The antinarcoleptic drug modafinil increases glutamate release in thalamic areas and hippocampus. NeuroReport 1997 8 13 2883 2887 2-s2.0-0030875892 (Pubitemid 27394812)
65. Smart K., Desmond R. C., Poulos C. X., Zack M., Modafinil increases reward salience in a slot machine game in low and high impulsivity pathological gamblers. Neuropharmacology 2013 73 66 74 10.1016/j.neuropharm.2013.05.015
66. Tarrant N., Cavanna A. E., Rickards H., Pathological gambling associated with modafinil. Journal of Neuropsychiatry and Clinical Neurosciences 2010 22 1 E27 E28 2-s2.0-76749104352
67. Ladouceur R., Sylvain C., Boutin C., Lachance S., Doucet C., Leblond J., Group therapy for pathological gamblers: a cognitive approach. Behaviour Research and Therapy 2003 41 5 587 596 2-s2.0-0037403777 10.1016/S0005-7967(02) 00036-0 (Pubitemid 36438637)
68. Grant J. E., Kim S. W., Hollander E., Potenza M. N., Predicting response to opiate antagonists and placebo in the treatment of pathological gambling. Psychopharmacology 2008 200 4 521 527 2-s2.0-52649104059 10.1007/s00213-008- 1235-3
69. Tanaka K., Watase K., Manabe T., Epilepsy and exacerbation of brain injury in mice lacking the glutamate transporter GLT-1. Science 1997 276 5319 1699 1702 10.1126/science.276.5319.1699 (Pubitemid 27421977)
70. Sari Y., Sakai M., Weedman J. M., Rebec G. V., Bell R. L., Ceftriaxone, a beta-lactam antibiotic, reduces ethanol consumption in alcohol-preferring rats. Alcohol and Alcoholism 2011 46 3 239 246 2-s2.0-79955405349 10.1093/alcalc/agr023 agr023
71. Jeanblanc J., Coune F., Botia B., Naassila M., Brain-derived neurotrophic factor mediates the suppression of alcohol self-administration by memantine. Addiction Biology 2013 2-s2.0-84873938777 10.1111/adb.12039
72. Angelucci F., Ricci V., Gelfo F., BDNF serum levels in subjects developing or not post-traumatic stress disorder after trauma exposure. Brain and Cognition 2014 84 1 118 122 10.1016/j.bandc.2013.11.012
73. Angelucci F., Martinotti G., Gelfo F., Righino E., Conte G., Caltagirone C., Bria P., Ricci V., Enhanced BDNF serum levels in patients with severe pathological gambling. Addiction Biology 2013 18 4 749 751 2-s2.0-84879463143 10.1111/j.1369-1600.2011.00411.x